The re-emergence of intermediaries in the procurement of medicines by the Health Ministry is not just an administrative adjustment; it is a sobering indictment of how policy, when driven by rhetoric rather than rigour, can backfire with real consequences for ordinary citizens. Reports that some medicines are now costing up to five times more, coupled with widening supply gaps and shortages in hospitals, should concern every Namibian. More importantly, it demands a frank reflection on how we arrived at this point.
At the heart of the matter lies a familiar but dangerous pattern: the preference for performative, dramatic gestures over careful study and system-based reform.
The pharmaceutical industry is not a simple marketplace where goods move seamlessly from producer to consumer. It is a highly regulated, globally interconnected ecosystem involving manufacturers, distributors, compliance frameworks, logistics chains, and quality assurance mechanisms. For decades, Namibia has relied on this complex system to ensure that medicines reach its people safely and efficiently.
Yet, despite repeated warnings from experts, the ministry chose a different path, one shaped more by populist appeal than technical understanding. The narrative of “eliminating middlemen” was politically attractive. It resonated with public frustration about costs and corruption, and it created the impression of decisive leadership taking on entrenched inefficiencies. But as events are now showing, slogans do not replace systems.
Intermediaries in the pharmaceutical supply chain are not inherently exploitative actors. In many cases, they perform critical roles: aggregating demand, ensuring compliance with international standards, managing storage and distribution, and bridging logistical gaps between manufacturers and end users. Removing them without building equivalent capacity within the state is not reform; it is disruption without preparation.
What we are witnessing now appears to be the predictable outcome of such disruption. Medicines are becoming more expensive, not cheaper. Supply chains have been destabilised. Hospitals are reportedly facing shortages, placing both patients and healthcare workers in precarious positions. The very objective that justified the initial policy shift, affordability and accessibility, is now being undermined.
This situation underscores a broader lesson: new does not necessarily mean better. There is a tendency in governance, particularly in politically charged environments, to equate change with progress. But change, when not grounded in evidence and institutional readiness, can be regressive. Namibia has been importing medicines for decades. That system, while not perfect, was functional. It ensured continuity of supply and predictability of cost. Reforming such a system requires careful calibration, not abrupt dismantling.
What is particularly troubling is that many of these outcomes were foreseeable. The complexity of pharmaceutical procurement is not new information. The risks of bypassing established supply chains without adequate infrastructure are well documented globally. Yet, instead of undertaking a methodical review, consulting industry experts, piloting new approaches, and strengthening internal capacity, decisions appear to have been driven by urgency to demonstrate action.
There is a difference between fighting corruption and appearing to fight corruption. The former requires painstaking work: audits, institutional strengthening, transparent procurement systems, and accountability mechanisms. The latter often relies on bold announcements and sweeping declarations. While the language of “tough talk” may win public approval in the short term, it does little to address the structural realities of complex sectors like pharmaceuticals.
Indeed, populism and inexperience can be a costly combination. When policy is shaped to “play to the gallery” rather than to solve problems, the consequences are rarely immediate, but they are almost always severe. In this case, the cost is being measured not only in inflated prices but also in the availability of life-saving medicines. For patients waiting in clinics and hospitals, these are not abstract policy debates; they are matters of health and survival.
The return to intermediaries, therefore, should not be seen as a failure in itself, but rather as an opportunity for course correction. It is an implicit acknowledgement that the system cannot function on rhetoric alone. However, simply reverting to previous arrangements without addressing underlying issues would be equally short-sighted. The goal should not be to swing between extremes but to build a balanced, resilient procurement framework.
Such a framework would recognise the role of intermediaries while ensuring transparency and competitiveness. It would invest in local capacity where feasible, without compromising efficiency or quality. It would prioritise data-driven decision-making over political expediency. And, crucially, it would proceed incrementally, testing reforms, learning from outcomes, and adjusting accordingly.
Governance is, at its core, an exercise in humility. It requires acknowledging the limits of one’s knowledge and the complexity of the systems one seeks to change. The pharmaceutical sector, perhaps more than most, demands this humility. It is not a space where shortcuts yield sustainable results.
Namibia is now learning this lesson the hard way. The current challenges in medicine procurement are not merely operational hiccups; they are the consequences of decisions that prioritised optics over substance. As the country navigates this difficult moment, the imperative must be clear: move away from performative policymaking and toward thoughtful, evidence-based reform.
Because in the end, the true cost of getting it wrong is not measured in headlines or political capital; it is measured in the health and well-being of the nation.
